Skip to content
AnalystLens

Charles River Laboratories International Quarterly Report for Q2 Ended Jun 29, 2024

Filing Date
Filed August 7, 2024
Period End
June 29, 2024
Security
CRL
One revenue dollarkept$0.09
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported a quarter ended June 29, 2024 with total revenue of $1,026.1 milliona, down from $1,059.9 million in the prior-year quarter, a decrease of $33.8 million or 3.2%.

The filing attributes the decline primarily to lower volume in the DSA business, partially offset by higher Manufacturing revenue and the Noveprim acquisition. Operating income fell to $151.7 millionb (14.8% margin) from $164.9 million (15.6%), and net income available to common shareholders decreased to $90.0 million from $97.0 million. For the six months, revenue was $2,037.7 million, down 2.5%, and operating income was $277.6 million versus $332.8 million, with restructuring charges of $35.0 million in the period.

Cash flow from operations improved to $323.4 millionc for the six months from $257.5 million, driven by working capital improvements. Cash and cash equivalents fell to $179.2 million, and long-term debt, net and finance leases declined to $2,409.4 million from $2,647.1 million as the revolving facility was paid down. DSA backlog decreased to $2.2 billion from $2.5 billion, and management cited a more cautious spending environment among biopharmaceutical clients.

The company expects restructuring actions to yield more than $150 milliond in annualized cost savings, of which about $100 million affects fiscal 2024. The filing also details ongoing U.S. government investigations into non-human primate sourcing, a securities class action that was dismissed on July 1, 2024 and is now under appeal, and derivative lawsuits, with the company stating it cannot reasonably estimate potential exposure. On August 2, 2024, the Board approved a new $1.0 billion stock repurchase authorization replacing the prior program, which had $129.1 million remaining.

Key Highlights

  1. Total revenue of $1,026.1 million for the quarter, down 3.2% from $1,059.9 million, driven mainly by lower DSA volume
  2. Operating income of $151.7 million (14.8% margin) versus $164.9 million (15.6%) a year earlier, reflecting restructuring charges and higher operating costs
  3. DSA segment operating income fell to $138.4 million from $161.5 million, while Manufacturing operating income rose to $37.2 million from $24.4 million
  4. Six-month operating cash flow of $323.4 million, up from $257.5 million, with long-term debt reduced to $2,409.4 million from $2,647.1 million
  5. DSA backlog declined to $2.2 billion from $2.5 billion at fiscal year-end 2023 amid a more cautious client spending environment
  6. Restructuring initiatives expected to deliver more than $150 million in annualized cost savings, with about $100 million impacting fiscal 2024
  7. Securities class action dismissed July 1, 2024 with plaintiff appealing; new $1.0 billion share repurchase authorization approved August 2, 2024

Follow one dollar

Of each $1.00 of revenue in Q2 FY2024, Charles River Laboratories International kept $0.09.

  1. Revenue$1.03B100.0%
  2. Cost of revenue−$672.4M65.5%
  3. Gross profit$353.7M34.5%
  4. Operating costs−$202.1M19.7%
  5. Operating income$151.7M14.8%
  6. Interest, other & tax−$61.7M6.0%
  7. Net income$90.0M8.8%
Computed from 10-QQ2 FY2024filed August 7, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q2 FY2024 against Q2 FY2023

Line itemQ2 FY2024Q2 FY2023Change
Revenue$1.03B$1.03B−0.3%
Cost of Revenue$672.40M$651.72M+3.2%
Gross Profit$353.71M$377.65M−6.3%
SG&A Expenses$169.79M$174.85M−2.9%
Operating Income$151.65M$167.89M−9.7%
Net Income$89.99M$103.13M−12.7%
EPS (Basic)$1.75$2.02−13.4%
EPS (Diluted)$1.74$2.01−13.4%
Shares Outstanding (Basic)51.55M51.10M+0.9%
Shares Outstanding (Diluted)51.85M51.43M+0.8%

Frequently Asked Questions

  1. Why did revenue and operating income decline in the second quarter of 2024?

    The filing says the revenue decrease was primarily due to lower volume in the DSA business, partly offset by higher Manufacturing revenue and the Noveprim acquisition. Operating income declined due to lower revenue, higher operating costs across all businesses, and restructuring charges including severance, asset impairments, and site consolidation costs.

  2. How is the restructuring program expected to affect future results?

    The company incurred restructuring charges of $18.0 million in the quarter and $35.0 million for the six months, and expects actions taken and planned to yield more than $150 million in annualized cost savings, of which approximately $100 million affects fiscal 2024. Further multi-year footprint optimization initiatives are being finalized and their costs and savings are not included in these totals.

  3. What is the status of the non-human primate investigations and lawsuits?

    The DOJ, USFWS and SEC investigations are ongoing, and the company is cooperating; it cannot predict their outcome or potential fines or penalties. The securities class action was dismissed on July 1, 2024, and the plaintiff filed a notice of appeal on July 30, 2024. Derivative lawsuits remain pending, and the company cannot reasonably estimate potential exposure in these matters.

  4. How strong is the company's liquidity and debt position?

    Cash and cash equivalents were $179.2 million at June 29, 2024, and the revolving facility balance fell to $879.5 million from $1,129.2 million. The weighted average interest rate on debt was 4.64%. Management believes existing funds, operating cash flow and financing access are sufficient to fund operations for the foreseeable future.

  5. What capital allocation actions did the company take or announce?

    The company acquired the remaining 10% of an other redeemable noncontrolling interest for $12.0 million and repurchased no shares under its program during the six months, apart from $18.3 million of shares withheld for tax netting on stock awards. On August 2, 2024, the Board approved a new $1.0 billion stock repurchase authorization replacing the prior $1.3 billion program, which had $129.1 million remaining.